APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccine for Chickenpox

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Live Attenuated Vaccine for Chickenpox Market Outlook and Growth Opportunities 2026

30 December 2025197 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccine for Chickenpox Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccine for Chickenpox Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccine for Chickenpox Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccine for Chickenpox Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccine for Chickenpox Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccine for Chickenpox market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Vaccine for Chickenpox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Live Attenuated Vaccine for Chickenpox market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Live Attenuated Vaccine for Chickenpox market include GSK, BCHT, Biken, Green Cross, Keygen, Merck & Co lnc, Sanofi Pasteur, Beijing Institute of Biological Products Co., Ltd and Chengdu Institute of Biological Products Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Vaccine for Chickenpox market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Vaccine for Chickenpox and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Vaccine for Chickenpox sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Vaccine for Chickenpox market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Vaccine for Chickenpox Segment by Company

GSK

BCHT

Biken

Green Cross

Keygen

Merck & Co lnc

Sanofi Pasteur

Beijing Institute of Biological Products Co., Ltd

Chengdu Institute of Biological Products Co., Ltd

Kexing (Dalian) Vaccine Technology Co., Ltd

Shanghai Rongsheng Biopharmaceutical Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Changchun Baike Biotechnology Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Vaccine for Chickenpox Segment by Type

Child

Adult

Live Attenuated Vaccine for Chickenpox Segment by Application

Hospital

Clinic

Live Attenuated Vaccine for Chickenpox Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Live Attenuated Vaccine for Chickenpox status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Live Attenuated Vaccine for Chickenpox market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Live Attenuated Vaccine for Chickenpox significant trends, drivers, influence factors in global and regions.

6. To analyze Live Attenuated Vaccine for Chickenpox competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccine for Chickenpox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccine for Chickenpox and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccine for Chickenpox.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Vaccine for Chickenpox market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Vaccine for Chickenpox industry.

Chapter 3: Detailed analysis of Live Attenuated Vaccine for Chickenpox manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Live Attenuated Vaccine for Chickenpox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Live Attenuated Vaccine for Chickenpox in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Vaccine for Chickenpox Industry Trends Table 2. Live Attenuated Vaccine for Chickenpox Industry Drivers Table 3. Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges Table 4. Live Attenuated Vaccine for Chickenpox Industry Restraints Table 5. Global Live Attenuated Vaccine for Chickenpox Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Vaccine for Chickenpox Revenue Share by Company (2021-2026) Table 7. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Company (2021-2026) Table 9. Global Live Attenuated Vaccine for Chickenpox Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Live Attenuated Vaccine for Chickenpox Company Ranking, (2024-2026) & (USD Million) Table 11. Global Live Attenuated Vaccine for Chickenpox Key Company Manufacturing Base & Headquarters Table 12. Global Live Attenuated Vaccine for Chickenpox Company, Product Type & Application Table 13. Global Live Attenuated Vaccine for Chickenpox Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Vaccine for Chickenpox by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Child Table 18. Significant Companies of Adult Table 19. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Type (2021-2026) Table 23. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Type (2027-2032) Table 24. Global Live Attenuated Vaccine for Chickenpox Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Live Attenuated Vaccine for Chickenpox Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Live Attenuated Vaccine for Chickenpox Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Type (2021-2026) Table 28. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Application (2021-2026) Table 35. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Application (2027-2032) Table 36. Global Live Attenuated Vaccine for Chickenpox Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Live Attenuated Vaccine for Chickenpox Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Live Attenuated Vaccine for Chickenpox Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Application (2021-2026) Table 40. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Application (2027-2032) Table 41. Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2026) & (K Units) Table 43. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2021-2026) Table 44. Global Live Attenuated Vaccine for Chickenpox Sales by Region (2027-2032) & (K Units) Table 45. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region (2027-2032) Table 46. Global Live Attenuated Vaccine for Chickenpox Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Live Attenuated Vaccine for Chickenpox Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Region (2021-2026) Table 49. Global Live Attenuated Vaccine for Chickenpox Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Region (2027-2032) Table 51. Global Live Attenuated Vaccine for Chickenpox Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Live Attenuated Vaccine for Chickenpox Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Live Attenuated Vaccine for Chickenpox Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Live Attenuated Vaccine for Chickenpox Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026) & (K Units) Table 56. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2021-2026) Table 57. Global Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032) & (K Units) Table 58. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Country (2027-2032) Table 59. Global Live Attenuated Vaccine for Chickenpox Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Live Attenuated Vaccine for Chickenpox Sales Value Market Share by Country (2021-2026) Table 61. Global Live Attenuated Vaccine for Chickenpox Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Live Attenuated Vaccine for Chickenpox Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. GSK Live Attenuated Vaccine for Chickenpox Product Portfolio Table 67. GSK Recent Development Table 68. BCHT Company Information Table 69. BCHT Business Overview Table 70. BCHT Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio Table 72. BCHT Recent Development Table 73. Biken Company Information Table 74. Biken Business Overview Table 75. Biken Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Biken Live Attenuated Vaccine for Chickenpox Product Portfolio Table 77. Biken Recent Development Table 78. Green Cross Company Information Table 79. Green Cross Business Overview Table 80. Green Cross Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio Table 82. Green Cross Recent Development Table 83. Keygen Company Information Table 84. Keygen Business Overview Table 85. Keygen Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio Table 87. Keygen Recent Development Table 88. Merck & Co lnc Company Information Table 89. Merck & Co lnc Business Overview Table 90. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio Table 92. Merck & Co lnc Recent Development Table 93. Sanofi Pasteur Company Information Table 94. Sanofi Pasteur Business Overview Table 95. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio Table 97. Sanofi Pasteur Recent Development Table 98. Beijing Institute of Biological Products Co., Ltd Company Information Table 99. Beijing Institute of Biological Products Co., Ltd Business Overview Table 100. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 102. Beijing Institute of Biological Products Co., Ltd Recent Development Table 103. Chengdu Institute of Biological Products Co., Ltd Company Information Table 104. Chengdu Institute of Biological Products Co., Ltd Business Overview Table 105. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 107. Chengdu Institute of Biological Products Co., Ltd Recent Development Table 108. Kexing (Dalian) Vaccine Technology Co., Ltd Company Information Table 109. Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview Table 110. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 112. Kexing (Dalian) Vaccine Technology Co., Ltd Recent Development Table 113. Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information Table 114. Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview Table 115. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 117. Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Development Table 118. Shanghai Institute of Biological Products Co., Ltd Company Information Table 119. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 120. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 122. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 123. Changchun Baike Biotechnology Co., Ltd Company Information Table 124. Changchun Baike Biotechnology Co., Ltd Business Overview Table 125. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 127. Changchun Baike Biotechnology Co., Ltd Recent Development Table 128. Changchun Qijian Biological Products Co., Ltd Company Information Table 129. Changchun Qijian Biological Products Co., Ltd Business Overview Table 130. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio Table 132. Changchun Qijian Biological Products Co., Ltd Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Live Attenuated Vaccine for Chickenpox Distributors List Table 136. Live Attenuated Vaccine for Chickenpox Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Live Attenuated Vaccine for Chickenpox Product Image Figure 2. Global Live Attenuated Vaccine for Chickenpox Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Vaccine for Chickenpox Sales (2021-2032) & (K Units) Figure 5. Global Live Attenuated Vaccine for Chickenpox Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Live Attenuated Vaccine for Chickenpox Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Type (2021-2032) Figure 14. Global Live Attenuated Vaccine for Chickenpox Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Live Attenuated Vaccine for Chickenpox Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Application (2021-2032) Figure 22. Global Live Attenuated Vaccine for Chickenpox Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Live Attenuated Vaccine for Chickenpox Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Application (2021-2032) Figure 25. Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Live Attenuated Vaccine for Chickenpox Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Live Attenuated Vaccine for Chickenpox Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032) & (US$ Million) Figure 30. North America Live Attenuated Vaccine for Chickenpox Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Live Attenuated Vaccine for Chickenpox Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Live Attenuated Vaccine for Chickenpox Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032) & (US$ Million) Figure 36. South America Live Attenuated Vaccine for Chickenpox Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Live Attenuated Vaccine for Chickenpox Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Live Attenuated Vaccine for Chickenpox Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Live Attenuated Vaccine for Chickenpox Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • BCHT
  • Biken
  • Green Cross
  • Keygen
  • Merck & Co lnc
  • Sanofi Pasteur
  • Beijing Institute of Biological Products Co., Ltd
  • Chengdu Institute of Biological Products Co., Ltd
  • Kexing (Dalian) Vaccine Technology Co., Ltd
  • Shanghai Rongsheng Biopharmaceutical Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Changchun Baike Biotechnology Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032)
  4. 1.2.2 Global Live Attenuated Vaccine for Chickenpox Sales Volume (2021-2032)
  5. 1.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Live Attenuated Vaccine for Chickenpox Market Dynamics
  1. 2.1 Live Attenuated Vaccine for Chickenpox Industry Trends
  2. 2.2 Live Attenuated Vaccine for Chickenpox Industry Drivers
  3. 2.3 Live Attenuated Vaccine for Chickenpox Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccine for Chickenpox Industry Restraints
3 Live Attenuated Vaccine for Chickenpox Market by Company
  1. 3.1 Global Live Attenuated Vaccine for Chickenpox Company Revenue Ranking in 2025
  2. 3.2 Global Live Attenuated Vaccine for Chickenpox Revenue by Company (2021-2026)
  3. 3.3 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Company (2021-2026)
  4. 3.4 Global Live Attenuated Vaccine for Chickenpox Average Price by Company (2021-2026)
  5. 3.5 Global Live Attenuated Vaccine for Chickenpox Company Ranking (2024-2026)
  6. 3.6 Global Live Attenuated Vaccine for Chickenpox Company Manufacturing Base and Headquarters
  7. 3.7 Global Live Attenuated Vaccine for Chickenpox Company Product Type and Application
  8. 3.8 Global Live Attenuated Vaccine for Chickenpox Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Live Attenuated Vaccine for Chickenpox Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Live Attenuated Vaccine for Chickenpox Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Live Attenuated Vaccine for Chickenpox Market by Type
  1. 4.1 Live Attenuated Vaccine for Chickenpox Type Introduction
  2. 4.1.1 Child
  3. 4.1.2 Adult
  4. 4.2 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type
  5. 4.2.1 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Live Attenuated Vaccine for Chickenpox Sales Value by Type
  9. 4.3.1 Global Live Attenuated Vaccine for Chickenpox Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live Attenuated Vaccine for Chickenpox Sales Value by Type (2021-2032)
  11. 4.3.3 Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Type (2021-2032)
5 Live Attenuated Vaccine for Chickenpox Market by Application
  1. 5.1 Live Attenuated Vaccine for Chickenpox Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application
  5. 5.2.1 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Live Attenuated Vaccine for Chickenpox Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Live Attenuated Vaccine for Chickenpox Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Live Attenuated Vaccine for Chickenpox Sales Value by Application
  9. 5.3.1 Global Live Attenuated Vaccine for Chickenpox Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Live Attenuated Vaccine for Chickenpox Sales Value by Application (2021-2032)
  11. 5.3.3 Global Live Attenuated Vaccine for Chickenpox Sales Value Share by Application (2021-2032)
6 Live Attenuated Vaccine for Chickenpox Regional Sales and Value Analysis
  1. 6.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Vaccine for Chickenpox Sales by Region: 2021-2026
  4. 6.2.2 Global Live Attenuated Vaccine for Chickenpox Sales by Region (2027-2032)
  5. 6.3 Global Live Attenuated Vaccine for Chickenpox Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Live Attenuated Vaccine for Chickenpox Sales Value by Region (2021-2032)
  7. 6.4.1 Global Live Attenuated Vaccine for Chickenpox Sales Value by Region: 2021-2026
  8. 6.4.2 Global Live Attenuated Vaccine for Chickenpox Sales Value by Region (2027-2032)
  9. 6.5 Global Live Attenuated Vaccine for Chickenpox Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032)
  12. 6.6.2 North America Live Attenuated Vaccine for Chickenpox Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032)
  15. 6.7.2 Europe Live Attenuated Vaccine for Chickenpox Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Live Attenuated Vaccine for Chickenpox Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032)
  21. 6.9.2 South America Live Attenuated Vaccine for Chickenpox Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Live Attenuated Vaccine for Chickenpox Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Live Attenuated Vaccine for Chickenpox Sales Value Share by Country, 2025 VS 2032
7 Live Attenuated Vaccine for Chickenpox Country-level Sales and Value Analysis
  1. 7.1 Global Live Attenuated Vaccine for Chickenpox Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Live Attenuated Vaccine for Chickenpox Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2032)
  4. 7.3.1 Global Live Attenuated Vaccine for Chickenpox Sales by Country (2021-2026)
  5. 7.3.2 Global Live Attenuated Vaccine for Chickenpox Sales by Country (2027-2032)
  6. 7.4 Global Live Attenuated Vaccine for Chickenpox Sales Value by Country (2021-2032)
  7. 7.4.1 Global Live Attenuated Vaccine for Chickenpox Sales Value by Country (2021-2026)
  8. 7.4.2 Global Live Attenuated Vaccine for Chickenpox Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Live Attenuated Vaccine for Chickenpox Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Live Attenuated Vaccine for Chickenpox Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Live Attenuated Vaccine for Chickenpox Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Live Attenuated Vaccine for Chickenpox Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 BCHT
  8. 8.2.1 BCHT Company Information
  9. 8.2.2 BCHT Business Overview
  10. 8.2.3 BCHT Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BCHT Live Attenuated Vaccine for Chickenpox Product Portfolio
  12. 8.2.5 BCHT Recent Developments
  13. 8.3 Biken
  14. 8.3.1 Biken Company Information
  15. 8.3.2 Biken Business Overview
  16. 8.3.3 Biken Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biken Live Attenuated Vaccine for Chickenpox Product Portfolio
  18. 8.3.5 Biken Recent Developments
  19. 8.4 Green Cross
  20. 8.4.1 Green Cross Company Information
  21. 8.4.2 Green Cross Business Overview
  22. 8.4.3 Green Cross Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Green Cross Live Attenuated Vaccine for Chickenpox Product Portfolio
  24. 8.4.5 Green Cross Recent Developments
  25. 8.5 Keygen
  26. 8.5.1 Keygen Company Information
  27. 8.5.2 Keygen Business Overview
  28. 8.5.3 Keygen Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Keygen Live Attenuated Vaccine for Chickenpox Product Portfolio
  30. 8.5.5 Keygen Recent Developments
  31. 8.6 Merck & Co lnc
  32. 8.6.1 Merck & Co lnc Company Information
  33. 8.6.2 Merck & Co lnc Business Overview
  34. 8.6.3 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co lnc Live Attenuated Vaccine for Chickenpox Product Portfolio
  36. 8.6.5 Merck & Co lnc Recent Developments
  37. 8.7 Sanofi Pasteur
  38. 8.7.1 Sanofi Pasteur Company Information
  39. 8.7.2 Sanofi Pasteur Business Overview
  40. 8.7.3 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Pasteur Live Attenuated Vaccine for Chickenpox Product Portfolio
  42. 8.7.5 Sanofi Pasteur Recent Developments
  43. 8.8 Beijing Institute of Biological Products Co., Ltd
  44. 8.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 8.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 8.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  48. 8.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 8.9 Chengdu Institute of Biological Products Co., Ltd
  50. 8.9.1 Chengdu Institute of Biological Products Co., Ltd Company Information
  51. 8.9.2 Chengdu Institute of Biological Products Co., Ltd Business Overview
  52. 8.9.3 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Chengdu Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  54. 8.9.5 Chengdu Institute of Biological Products Co., Ltd Recent Developments
  55. 8.10 Kexing (Dalian) Vaccine Technology Co., Ltd
  56. 8.10.1 Kexing (Dalian) Vaccine Technology Co., Ltd Company Information
  57. 8.10.2 Kexing (Dalian) Vaccine Technology Co., Ltd Business Overview
  58. 8.10.3 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Kexing (Dalian) Vaccine Technology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  60. 8.10.5 Kexing (Dalian) Vaccine Technology Co., Ltd Recent Developments
  61. 8.11 Shanghai Rongsheng Biopharmaceutical Co., Ltd
  62. 8.11.1 Shanghai Rongsheng Biopharmaceutical Co., Ltd Company Information
  63. 8.11.2 Shanghai Rongsheng Biopharmaceutical Co., Ltd Business Overview
  64. 8.11.3 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shanghai Rongsheng Biopharmaceutical Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  66. 8.11.5 Shanghai Rongsheng Biopharmaceutical Co., Ltd Recent Developments
  67. 8.12 Shanghai Institute of Biological Products Co., Ltd
  68. 8.12.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  69. 8.12.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  70. 8.12.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  72. 8.12.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  73. 8.13 Changchun Baike Biotechnology Co., Ltd
  74. 8.13.1 Changchun Baike Biotechnology Co., Ltd Company Information
  75. 8.13.2 Changchun Baike Biotechnology Co., Ltd Business Overview
  76. 8.13.3 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Changchun Baike Biotechnology Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  78. 8.13.5 Changchun Baike Biotechnology Co., Ltd Recent Developments
  79. 8.14 Changchun Qijian Biological Products Co., Ltd
  80. 8.14.1 Changchun Qijian Biological Products Co., Ltd Company Information
  81. 8.14.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  82. 8.14.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Vaccine for Chickenpox Product Portfolio
  84. 8.14.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Vaccine for Chickenpox Value Chain Analysis
  2. 9.1.1 Live Attenuated Vaccine for Chickenpox Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Vaccine for Chickenpox Sales Mode & Process
  6. 9.2 Live Attenuated Vaccine for Chickenpox Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Vaccine for Chickenpox Distributors
  9. 9.2.3 Live Attenuated Vaccine for Chickenpox Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst